MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depression
MIAMI, May 21, 2024...

Related Keywords

Mexico ,Canada ,Miami ,Florida ,United States ,Mexican ,Canadian ,Erez Aminov ,Amitabh Gulati ,Itzchak Angel ,Sloan Kettering ,Pharmaceuticals Inc ,Securities Exchange ,Board Member Of Cancer Pain Research Consortium ,Nasdaq ,National Cancer Institute ,Sloan Kettering Cancer Center ,Pharmaceuticals In Discussions ,Drug Administration ,Pharmaseed Ltd ,Sloan Kettering Institute ,Memorial Sloan Kettering Cancer Center ,Us Drug Enforcement Administration ,Memorial Sloan Kettering ,Preclinical Cancer Pain ,Director Chronic Pain ,Board Member ,Cancer Pain Research ,Investigational New Drug Application ,Chief Scientific Advisor ,Enforcement Administration ,Controlled Substances Act ,World Report ,Securities Act ,Securities Exchange Act ,Annual Report ,Cancer Pain ,Cancer Institute ,